This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...
REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...
This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...
Study Objective: Compare longitudinal HIV-1 antibody responses among HIV-1 infected participants that either did or did not...
